The incidence of specific mutations, the percentage of targetable alterations, and the existence of immunotherapeutic biomarkers (e.g., TMB, MSI, PD-L1) were thoroughly explored in order to better understand the molecular tumor subtypes and to recognize the real-world likelihood of incorporating newer agents in the management of PDAC. The gene discussed is CD274; the disease is neoplasm.